Breast Cancer
This category lists medicines used in the treatment of breast cancer, spanning several distinct treatment approaches. Which is relevant depends on the tumour’s receptor status and genetic profile — hormone receptor status, HER2 status and BRCA mutation status all shape the decision, which is why treatment follows testing. The range here includes CDK4/6 inhibitors such as palbociclib, HER2-targeted agents such as tucatinib and neratinib, the PARP inhibitor olaparib, the PI3K inhibitor alpelisib, and cytotoxic agents including docetaxel.
Generic versions of several of these are available from licensed manufacturers. Generic palbociclib contains the same active ingredient at the same strength as branded Ibrance, and generic olaparib matches Lynparza. As elsewhere in our oncology range, the comparison is drawn on active ingredient, strength and dose form alongside cost — not on outcomes. Nothing here should be read as a claim that one treatment is more effective than another.
All breast cancer medicines are prescription-only and are prescribed and monitored by an oncology specialist, with the medicine, dose and duration determined by your diagnosis and treatment plan. A valid prescription is required before any order can be dispensed, and worldwide delivery is available. For wider background on cancer treatment and how generic oncology medicines are sourced, see our cancer medicines hub. Used as prescribed by a licensed medical professional.
